Brief Title
Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells
Official Title
A Phase One, Open Label, Single Arm Study to Demonstrate the Safety of Antria Cell Preparation Process During Facial Fat Grafting Assisted With Autologous, Adipose Derived Stromal Vascular Fraction (SVF)
Brief Summary
The primary purpose of this study is to demonstrate the safety of injecting the Stromal Vascular Fraction (SVF) [containing Adipose Derived Stem Cells (ADSCs)] enriched fat grafts into regions of the face that require enhancement. The safety of SVF will be evaluated throughout the course of the study phase through the assessment of laboratory values, physical examinations, adverse events, safety phone calls etc.
Study Phase
Phase 1
Study Type
Interventional
Primary Outcome
To evaluate the safety of the administration of a concentrated SVF-enriched fat graft by monitoring the number and types of adverse events, and via physical examinations, vital signs, 12-lead ECGs, blood draws (CBC/LFT/BMP), and urinalysis.
Secondary Outcome
To demonstrate the efficacy of the addition of autologous SVF isolated via Antria Cell Preparation Process by observing graft survival time, volume, and quality of facial re-contouring
Condition
Lipoatrophy
Intervention
SVF
Study Arms / Comparison Groups
SVF-Enriched Lipoinjection
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Biological
Estimated Enrollment
6
Start Date
April 2013
Completion Date
January 2015
Primary Completion Date
January 2015
Eligibility Criteria
Inclusion Criteria: 1. Female or Male, Age 18 years or older 2. Subjects that are scheduled for liposuction and facial fat grafting procedures for cosmetic purposes 3. Facial volume defects which could be treated with a total graft volume of between 1mL and 50mL 4. BMI between and including 23 and 28 5. Able to understand and provide written and verbal informed consent Exclusion Criteria: 1. Currently taking or have taken NSAIDs within last two weeks or corticosteroids within the last six weeks prior to screening 2. Diagnosis of any of the following medical conditions: - Active malignancy (diagnosed within 5 years), except for treated non-melanoma skin cancer or other non-invasive or in-situ neoplasm - Active infection - Type I or Type II Diabetes 3. Subjects who are unlikely to comply with the protocol (e.g., uncooperative attitude, inability to return for subsequent visits, dementia, and/or otherwise considered by the Investigator to be unlikely to complete the study) 4. Subjects with a known drug or alcohol dependence within the past 12 months as judged by the Investigator 5. Subjects with major illnesses involving the renal, hepatic, cardiovascular, and/or nervous systems 6. Subjects with elevated kidney and/or liver functions 7. Any other disease condition or laboratory results that in the opinion of the investigator may be clinically significant and render the subject inappropriate for the study procedure(s), may alter the accuracy of study results, or increase risk for subjects. 8. Subjects with life-expectancies less than 9 months 9. Subjects with known collagenase allergies 10. Subjects with idiopathic or drug-induced coagulopathy 11. Pregnant females 12. On radiotherapy or chemotherapy agents 13. Taking strong CYP450 inhibitors such as protease inhibitors (ritonavir, indinavir, nelfinavir, saquinavir), macrolide antibiotics (clarithromycin, telithromycin), chloramphenicol, azole antibiotics (ketoconazole, itraconazole) and nefazodone. 14. Subjects with a history of keloids or hypertrophic scar formations
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Shahram Rahimian, MD, PhD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT01828723
Organization ID
SSVF0001
Responsible Party
Sponsor
Study Sponsor
Antria
Study Sponsor
Shahram Rahimian, MD, PhD, Principal Investigator, Antria Inc.
Verification Date
January 2015